Topic Listing for Vical

Academic Research Institutions Account Control Agreements
Accruals Potential Disallowed Costs Government Contracts Achievement 2007 Corporate Individual Goals
Achievement 2008 Corporate Individual Goals Additional Collateral Rider
Adjustment Shares Adjuvant Development
Administration Advances Rapidresponse Dna Vaccine Platform
Adverse Events Field Gene Therapy Respect Product Candidates Adverse Events Perception Field Gene Therapy Respect Product
Aggregated Option Exercises 2004 Year-end Values Aggregated Option Exercises 2005 Year-end Values
Agreement Dated 1991 Agreement Sell Purchase Shares Placement Agents
Allovectin-7 Allovectin-7 Size1
Amended Restated Stock Incentive Plan Amendment
Amendment Restated Certificate Incorporation Amendment Stock Incentive Plan
Anges Anges License
Anges Research Development Agreement Angiogenesis Partner Advancing Toward Approval
Angiogenesis Partner Advancing Toward Approvals Angiogenesis Partners Advancing Toward Approvals
Annual Bonus Annual Meeting 2005
Annual Meeting 2006 Annual Meeting 2007
Anthrax Vaccine Anti-takeover Provisions Charter Documents Delaware Law Make Acquisition
Anti-takeover Provisions Stockholder Rights Plan Charter Documents Delaware Applications Dna Technology
Aqua Health Assignment
Assignment Form Audit Committee
Audit Committee Report Available Information
Awards Stock Incentive Plan B-2
Base Salary Basis Presentation
Before Vote Beneficial Owner Shares Registered Name Broker Bank
Beneficial Owner Vical Shares Vote Beneficial Ownership Reporting Compliance
Board Directors Executive Compensation Board Directors Recommends Vote Amendment Restated Certificate Incorporation
Board Directors Recommends Vote Election Each Named Nominee Board Directors Recommends Vote Election Named Nominee
Board Directors Recommends Vote Election Named Nominees Board Meetings
Books Records Business Segments
Business Strategy Cancer
Cancer Therapies Cancer Vaccines
Capitalization Valuation Long-lived Intangible Assets Cardiovascular
Cardiovascular Programs Cash Equivalents Marketable Securities
Ceo Compensation Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Certain Relationships Related Transactions Director Independence
Certification Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Change Accounting Firm Change Accounting Method Share-based Compensation
Change Control Severance Benefits Change Vote After Submitting Proxy
Changes Disagreements Accountants Accounting Financial Disclosure Changes Internal Control Over Financial Reporting
Changes Internal Controls Clinical Supply Terms
Closings Delivery Shares Funds Cmv
Cmv Grants Cmv License Agreement
Cmv Program Cmv Vaccine Program
Code Business Conduct Ethics Collaboration Licensing Agreements
Collateral Locations Commercial Application
Commercialization Manufacturing Commitments Contingencies
Committee Fees Committees Board Directors
Common Stock 001 Par Value Compared 2002
Compared 2003 Compared 2004
Compared 2005 Compared 2006
Compared 2007 Compared 2008
Comparison Cumulative Total Return Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Components Compensation Directors
Compensation Discussion Analysis Compensation Executive Officers
Compensation Philosophy Objectives Competition
Competition Technological Change Make Product Candidates Technologies Less Compliance Certificate
Composition Certain Balance Sheet Captions Comprehensive Loss
Concentrations Credit Risk Conclusion Regarding Effectiveness Disclosure Controls Procedures
Conference Call Webcast Scheduled Confidential
Confidential Treatment Requested Confidentiality
Consent Independent Registered Public Accounting Firm Consideration
Consulting Contract Grant Agreements
Contract Manufacturing Contract Manufacturing Navy Medical Research Center
Contract Manufacturing Revenue Contract Manufacturing Vrc
Contractual Obligations Contractual Obligations Off-balance Sheet Arrangements
Controls Procedures Corautus
Corautus Genetics Core Technology
Corporate Collaborators-in-licensing Corporate Collaborators-out-licensing
Corporate Goals Corporate Governance Guidelines
Correction Method Accounting Equipment Financing Arrangements Cradas
Credit Facility Critical Accounting Policies Estimates
Critical Limb Ischemia Collaborative Program Cross-collateral Cross-default Agreement
Current Report Pursuant Securities Exchange Act 1934 Date Currently Depend Parties Conduct Clinical Trials Initially Manufacture
Cytomegalovirus Vaccine Cytrx
Darpa Grant Date Report Earliest Event Reported 2005
Date Report Earliest Event Reported 2006 Date Report Earliest Event Reported 2007
Dated 2000 Definitions
Delivery Funds Delivery Shares
Department Defense Departure Directors Certain Officers Election Appointment Compensatory
Description Stock Incentive Plan Determination Executive Compensation
Develop Products Independently Developments Pandemic Influenza Vaccine
Dex Diligence
Diligence Obligations Director Compensation
Director Compensation Table Director Continuing Office Until 2009 Annual Meeting
Director Equity Awards Director Fees
Director Options Director Qualifications
Directors Continuing Office Until 2006 Annual Meeting Directors Continuing Office Until 2007 Annual Meeting
Directors Continuing Office Until 2008 Annual Meeting Directors Continuing Office Until 2010 Annual Meeting
Directors Continuing Office Until 2011 Annual Meeting Directors Executive Officers
Directors Executive Officers Corporate Governance Directors Stock Option Plan
Disclosure Know-how Dna Vaccines
Dna Vaccines Infectious Diseases Documents Incorporated Reference
Duration Amendment Termination Duration Amendments
Ecitals Ection Ayment Hares
Ection Djustment Hares Ection Dministration
Ection Ecurities Aws Ection Efinitions
Ection Erms Onditions Ptions Ection Erms Onditions Wards Ales
Ection Ligibility Ection Mployment Ights
Ection Stablishment Urpose Ection Tock Ubject Lan
Ection Uration Mendments Ection Xecution
Eetings Inutes Eferral Lection
Effect Certain Corporate Events Elayed Ssuance Tock Urchase Greement
Elayed Ssuance Tock Urchase Lection Greement Election Directors
Eligibility Eligibility Shares Subject Stock Incentive Plan
Employee Benefit Plan Employee Benefit Plans
Employees Employment Contracts Termination Change-in-control Agreements
Employment Rights Enforcement
Enhance Expand Technologies Entry Material Definitive Agreement
Equipment Financing Equipment Financing Obligations
Equity Compensation Plan Information Establishment Purpose
Estimates Evaluating Nominees Director
Exact Name Registrant Specified Charter Except Per Share Data
Executing Lock-up Agreements Execution
Executive Compensation Executive Officers Other Executives
Executive Officers Registrant Executive Sessions
Exhibits Expand Applications Technologies Through Strategic Collaborations
Explanations Explanatory
Facility Consolidation Facility Leases
Fair Value Financial Instruments Fair Value Measurements
Federal Income Tax Consequences Awards Stock Incentive Plan Federated Kaufmann Funds Invest Vical
Fees Chairman Audit Committee Board Directors Fees Equity Awards Chairman Board Directors
Fees Former Current Principal Accounting Firm Fees Options Chairman Board Directors
Fees Principal Accounting Firm Financial Covenants
Financial Statement Schedules Financial Statements
Financial Statements Exhibits Find Out Results Voting Annual Meeting
Fold Detach Here Form 10-k
Form 10-q Form Lock-up Agreement
Former Name Address Changed Since Last Report Forward-looking Statements
General General Employment
General Release Not Extend Claims Creditor Know Suspect Genetronics
Government Collaborators Government Grants
Government Regulation Government Research Grant Revenue
Government Research Grant Revenue Recognizes Revenues Federal Grants Grant
Grant Awarded Herpes Simplex Virus Grant License
Grants Awarded Grants Plan Based Awards
Hazardous Materials Business Claims Relating Improper Handling Storage Healthcare Reform Restrictions Reimbursement Limit Returns Potential Products
History Net Losses Expect Continue Incur Not Achieve Hiv Collaborative Program
Householding Proxy Materials Ical Ncorporated
Ignature Age Ollow Il-2
Impairment Long-lived Assets Important
In-licensing Agreements Income Taxes
Increasing Applications Vaxfectin Adjuvant Indemnification Provisions
Indemnity Insurance Independence
Independence Board Directors Independent Programs Targeting Infectious Diseases
Independently Developed Product Candidates Been Approved Sale Limited Independently Developed Products Been Approved Sale Limited Number
Index Index Exhibits
Index Financial Statements Individual Goals
Infectious Diseases Influenza
Influenza Program Influenza Vaccine
Infringement Initially Depend Parties Manufacture Product Candidates Commercially
Inovio Intangible Assets
Integration Intellectual Property
International Aids Vaccine Initiative Interpretation
Introduction Investor Questionnaire
Invitrogen Corporation Iscellaneous
Issuance Common Stock Issuance Preferred Stock Adversely Affect Common Stockholders
Issuer Purchases Equity Securities Ithholding Bligations
Jill Church Key Elements Executive Compensation
Legal Proceedings Legal Proceedings Obtain Defend Patents Litigation Third-party Claims
License Agreement License Grants Anges
License Royalty Agreements License Royalty Revenue
Life Technologies Limitations
Limited Experience Manufacturing Product Candidates Commercial Quantities Not Liquidity Capital Resources
Loans Long-term Incentives
Long-term Investments Lose Key Personnel Unable Attract Retain Additional Not
Managements Report Internal Control Over Financial Reporting Manner Transfer
Manufacturing Process Development Manufacturing Production Costs
Market Registrants Common Equity Related Stockholder Matters Market Registrants Common Equity Related Stockholder Matters Issuer
Marketing Sales Experience Unable Develop Own Capability Not Merck
Merck License Agreement Merck Option Exercise
Merial Metastatic Melanoma
Milestone Payments Miscellaneous
Miscellaneous Provisions Names
Navy Need Additional Capital Future Not Available Curtail Cease
Negative Conditions Global Credit Markets Impair Liquidity Portion Net Loss Per Share
New Research Collaboration Nih Avian Influenza Grant
Nih Contracts Nih Grants
Nih Vaccine Research Center Nominating Governance Committee
Nominee Nominee Election Three-year Term Expiring 2009 Annual Meeting
Nominee Election Three-year Term Expiring 2012 Annual Meeting Nominees
Nominees Election Three-year Term Expiring 2008 Annual Meeting Nominees Election Three-year Term Expiring 2010 Annual Meeting
Nominees Election Three-year Term Expiring 2011 Annual Meeting Non-employee Director Compensation Policy
Nonqualified Deferred Compensation Table Not Able Identify Reach Agreement Potential Partner Further
Notice Exercise Notices
Notices Applicable Law Number 000-21088
Office Naval Research Omposition
Option Exercises Stock Vested Option Grants 2004
Option Grants 2005 Organization Business Activity
Other Other Balance Sheet Accounts
Other Cancer Programs Other Compensation
Other Contingencies Other Contract Grant Agreements
Other Infectious Diseases Other Information
Other Matters Other Research Licensing Agreements
Other Significant Events Out-licensing Cancer Targets
Outstanding Equity Awards Year-end Overview
Pandemic Influenza Vaccine Parachute Payments
Part Part Other Information
Patent Applications Maintenance Patents
Patents Proprietary Rights Not Provide Benefit Others Prevent Payable
Paying Proxy Solicitation Payment Shares
Payments Payments Others
Payments Reports Record-keeping Payments Timing Adjustments
Performance Graph Performance Measurement Comparison
Permitted Indebtedness Permitted Liens
Please Indicate Compliance Status Circling Yes Heading Complies Potential Payments Termination Change Control
Pre-approval Policies Procedures Principal Accountant Fees Services
Pro Forma Information Sfas 123 Periods Prior Adoption Product Development
Products Been Approved Sale Limited Number Independent Product Properties
Property Equipment Protein Vaccines
Proxy Statement Annual Report Available Wwwproxyvotecom Purchase Agreement
Purpose Pursue Contract Manufacturing Opportunities
Quantitative Qualitative Disclosures Market Risk Ratification Selection Independent Auditors
Receiving Materials Recent Accounting Pronouncements
Recent Accounting Standards Recent Contract Grant Activities
Recent Contract Grant License Activities Recent Events
Reclassifications Registrants Telephone Number Including Area Code 858 646-1100
Registration Recordation Regulatory Approval Process Expensive Time Consuming Uncertain Prevent
Related Parties Related Stockholder Matters
Related-party Transactions Relocation Costs
Remainder Page Intentionally Left Blank Report Audit Committee Board Directors
Report Independent Registered Public Accounting Firm Reports
Representations Representations Warranties
Representations Warranties Covenants Investor Research Development Agreement
Research Development Costs Research Development Expenses
Research Development Manufacturing Programs Research Institutions
Restricted Cash Equivalents Restricted Cash Equivalents Marketable Securities
Restricted Cash Marketable Securities Restricted Marketable Securities
Restricted Marketable Securities Cash Equivalents Restructuring Activities Result Management Distractions Operational Disruptions Other
Restructuring Costs Results Operations
Results Operations Financial Condition Revenue Recognition
Risk Factors Risk Securities Class Action Litigation Due Expected Stock
Salary Continuation San Diego 92121-4340
Sanofi-aventis Sarbanes-oxley Act 2002
Schedule 14a Schedule 14a Information
Schedules Exhibits Securities Exchange Act 1934
Securities Laws Securities Purchase Agreement
Securities Registered Pursuant Act Security Deposit Pledge Agreement
Security Ownership Certain Beneficial Owners Security Ownership Certain Beneficial Owners Management
Security Ownership Certain Beneficial Owners Management Related Stockholder Security Ownership Directors Executive Officers
Security Ownership Directors Named Executive Officers Severance Benefits
Share-based Compensation Signature
Signature Pages Follow Signatures
Significant Contracts Grants License Royalty Agreements Significant Milestones Cancer Program
Significant Milestones Cancer Programs Significant Portion Revenue Derived Agreements Government Agencies Subject
Significant Product Liability Exposure Significant Progress Influenza Program
Significant Progress Vaxfectin Adjuvant Stock Incentive Plan
Stock Option Grants Exercises Stock Plan Committee
Stock Price Continue Highly Volatile Not Able Resell Stock Price Performance Graph
Stock Purchase Agreement Stock Subject Plan
Stock-based Compensation Stockholder Communications Board Directors
Stockholder Meeting Held 2009 Stockholder Nominations
Stockholder Proposals Due Next Annual Meeting Stockholder Record
Stockholder Record Shares Registered Name Stockholder Record Vical Shares Cast Vote
Stockholders Equity Sublicensing
Submission Matters Vote Security Holders Subscription Agreement
Subsequent Events Summary Amendment
Summary Compensation Table Summary Quarterly Financial Information
Tax Accounting Implications Temasek Holdings Invest Vical
Temasek Holdings Private Limited Term License
Term Termination Termination
Termination Based Compensation Termination Cause
Termination Employment Terms Conditions
Terms Conditions Awards Sales Terms Conditions Options
Terms Options Terms Shares Offered Sale
Title Class Tockholders Ical Ncorporated
Trials United States
Unregistered Sale Equity Securities Unregistered Sales Equity Securities
Unresolved Staff Comments Update Government Collaborations
Urpose Olicy Uthority
Uties Cope Mployment Vaxfectin
Veterinary Veterinary Applications
Via Hand Delivery Vical
Vical Announces News Release Conference Call Schedule Discuss Vical Announces Pricing Common Stock Registered Direct Offering
Vical Completes Registered Direct Offering Vical Grants Options Merck Cancer Vaccines
Vical Incorporated Vical Pay Such Remaining Expenses Including Manufacturing Costs
Vical Raise 125 Registered Direct Offering Vical Raise 154 Registered Direct Offering
Vical Reports 2005 Financial Results Vical Reports 2008 Financial Results Progress Product Development
Vical Reports 2009 Financial Results Progress Key Programs Vical Reports 2009 Financial Results Updates Progress Key
Vice President Chief Financial Officer Secretary Viii- General
Vijay Samant Vote
Vote Annual Meeting Votes
Votes Counted Votes Needed Approve Each Proposal
Warf-vical Patent Shall Mean Exclusively Licensed Vical Pursuant Warranties Limitation Liability
What Mean Receive Notice Proxy Card What Mean Receive Proxy Card
What Quorum Requirement What Received Notice Regarding Availability Proxy Materials
What Return Proxy Card Not Make Specific Choices What Shares Not Registered Directly Name Held Street
What Types Votes Permitted Each Proposal What Voting
Wisconsin Alumni Research Foundation University Michigan License Agreements Wistar Institute 2008 Licensed Exclusive Worldwide Rights Wistars
Witnesseth Xvi Notices
Xvii Miscellaneous 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki